Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Shareholder mtg???
Was it ever on the website under Upcoming Events??? I looked for it there a few weeks ago and it was not.
I also looked in other sections of website and could not find it because I wanted to know dates, was thinking about going, I never found it anywhere but I could have missed it.
People are saying it was taken off website. In what section was it in before being taken down?
What up fool...
Thanks for the creds. Hope this turns into another SNIC (Sonic Solutions). Made 6X on my money on that and I had a large position.
That took (me) four to get there and it was a rough ride to for a while also.
It's cool CP
Been in the stock six years. I knew Jay before he was with Peregrine. He is a good guy. He has never told me anything since joining Peregrine that violates any SEC rule. Though I wish he would.
I don't post things that aren't true. I also don't speculate on all the things might happen. I leave the science to the science guys. Though I do know a lot about the science and that's why I got into the stock.
I just hope all this stuff going on is positive. I believe it is. If not my wife will be castrating me.
FTM
Jay did not say scheduling conflict in my email. Interesting.
He will not answer that question. So not going to ask. You can.
Jake I sent back the exact same question about MOS being extended. Would that be enough to present or too little info?
From Jay on EU conference
Email to Jay last night;
Jay now everyone is talking about
the EU conference with the posters
being taken down off their site? But conference is still on the Peregrine
website. Is there anything you can tell me? Are we still presenting
there?
Verbatim... Copied from email Jay sent back:
Due to the magnitude and extent of data we presented at the Chicago
Multidisciplinary Symposium in Thoracic Oncology, ESMO is reevaluating whether we would have anything new of substance to present.
I can post the email
If everyone wants. But some will think I made it up but I am not making this up.
I did send to my bro (Volgoat) so he can verify.
I sent another email to Jay asking him about the EU conference. Why are the posters down on EU website but it is still on the peregrine website?
Who knows if he will respond? Especially after I posted the other information. But I would think Jay would know that I was going to post it. He knows all about IHUB as a few on here can attest to.
KT - that is what he wrote
No BS!!!
Just hope Jay is not mad I shared eom
I promise is no joke
what I was told via email. If that is what you are referring to as a joke.
Got wireless on the plane just to watch PPer and do some work too. Did not expense it though because will primarily be watchinng PPer. Hard to work.
Sent email back
Saying... Yikes could not someone else have gone, like you? Asked who was presenting anyway?
Could all be true? I hope not. Seems like they would have someone to go last minute. Unless don't care anymor for whatever reason. On a plane gotta go.
Sent Jay email back
Saying. Yikes no one else could present like
maybe you? Jay knows a lot. Also asked who was parenting anyway.
Jay knows will post on IHub. On a plane gotta go.
Per Jay at PPHM
Not attending due to management personnel family issue.
Sent email to Jay
At PPHM. No response. I know Jay. So strange has not answered???
OT IHub App
Just downloaded the iPhone app for IHub. Pretty damn cool. Can read messages send messages.
Go PPHM.
When is the shareholders meeting?
Thurly - Pancreatic Cancer
Stupid question... I would assume they started treating some patients in Jan 2011 or as soon as they enrolled correct?
Eyebuystox... when is Op Ex? EOM
Entdoc... irradiation.
I kept waiting for them to say Bavi may work even better here vs chemo by exposing more PS but they never did that I heard.
Entdoc quote:
FTM, you ask, "Any other ideas?" Lots. Start with Bavituximab + irradiation therapy. This is an indication that should have been the beginning...the opening salvo...of Bavi ued in combination therapy. IMO it was an error to have begun clinical trials with chemo + Bavi, and nothing short of a miracle that it shows significant activity against horrendous disease (metastatic lung cancer). But at the time, with its desperate fiancial situation, chemo trials in India and Russia were the only straw we could grasp. There are so many advancements in specific targeted irradiation now. What an opportunity in virtually every cancer treated with irradiation. Next? Bavi plus surgery. Bavi in less advanced cases? Bavi w. radioactive iodine (as in PPHM's RAI bearing MAB Cotara). And as mentioned before this week, since Bavi can cross the nasal mucosa, a preventive in the form of a nose spray? The price drop today speaks volumes for what the wall street crowd must do to put food on the table.
Bought another 2600 at 3.82...
Doing my part... holding 37,400 shares. Go PPer.
Carlun123... if people / institutions are smart...
the catalyst was Friday. How many catalysts do you want, one per day? Remember MOS has not been met yet either!
Do not know why they do not mention this more BOLDLY in CC and in PRs? Anybody?
Wook... I was gonna buy $20K today but held
off thinking you were going on Cramer. Glad you are not going on the show. Odds were not in Longs favor at all.
Wook...
That sounds pretty good. I think at this point, if Cramer is going to talk about PPHM, we might as well frame the discussion / question.
Good afternoon Jim,
Peregrine is on a wild ride, You say that investors should have one Speculative stock in their portfolio. Your last statement about Peregrine Pharmaceuticals was "that if they came up with good Non Small Cell Lung Cancer result they were going to be OK." They just announced Friday that they doubled Median Overall Survival which was statistically significant, does that qualify and which BP could benefit the most with Peregrine as a Partner?
He may trash us if you call or do not call at this point???
If Wook does not call in will...
Cramer blast us anyway due to prepared response by Cramer already?
Wook...
You trying to drive the price down so can buy more? You trust Cramer you are crazy. Read his book when he ran his hedge fund.
Be great if he said he loved PPHM but I doubt that will be his answer! He may truly love it but if he does he will say sell so he can buy.
I think they have a partner(s)...
Said about 3 times they want them on board for meeting with FDA which is 60 days or less out!
Giving us clues!
I am buying another $20k of stock today.
Sweet Tek..
Whoop whoop... girls with no teeth is good stuff. She got a name?
When Wright Bros flew....
many newspapers at the time would not even report it because everyone knew, it had been proven by scientists that flight by man was impossible.
Johhny Rocket - Wife has given permission to buy
another 20k of PPHM, bring it down for an hour or two. JR need your help. What your crystal ball saying?
Yes, this is the wife who wanted to sell it all at .47.
I wish PPHM would do a stand alone PR Monday...
on updated interim MOS to follow up to Friday. Clear it up for all the media that still will improve. Keep em guessing, keep us in the news.
Thurly I understand the science community, and us, will pick up on it but you have to be very clear with the press... they ain't that smart. Now TV people like Thurly are different, Thurly probably smartest of the bunch of them too.
The media in general just reads what you give them and that's about the extent of it. Agree the Chicago Trib did an excellent job but they were about it on recognizing this was INTERIM DATA and will improve.
I sent an email to Jay on this earlier today. I know Jay so hope he reads it; he is probably getting a lot of emails now.
Hey Tek...
Is that Tessi May's sister behind her? I like her too but she is a little small.
I picked a helluva a time to give up drinking on Monday of this week. Hard not to have a celebratory one on Friday but I stuck to it, need to quit unfortunately.
Sunstar...
I do not see why PPHM and Dr. Gerber underplayed the "Interim Data" part of the story??
Don't mind paying Cap Gains as they are now
But if the Gov't does not get on the Taxmageddon issue... Cap Gains will go up a lot, as will Dividend taxes. Market will tank along with the economy.
Why give Gov't more to waste, 16 Trillion in debt now. If you lose money you get to write off 3 grand a year. Freakin joke.
No one put enuf emphasis on MOS not being reached yet
It was just slid in their quietly, if wanted people to report on it then they should have repeated it several times with GUSTO.
In PPHM press release they just say Interim Data. Maybe saving for Monday CC. They should say in release on Monday in BOLD CAPS that MOS is great now but still has not been reached.
PPHM Press Release from Friday:
Interim Data From Peregrine's Phase II Trial in Second-Line Non-Small Cell Lung Cancer Demonstrate Doubling of Median Overall Survival in Bavituximab-Containing Arms
TUSTIN, CA -- (Marketwire) -- 09/07/12 --
•Interim Data from Double-Blind, Placebo-Controlled Trial Presented at Late-Breaking Plenary Session at Leading Oncology Symposium
•Data Show Statistically Significant Improvement in Overall Survival for Patients Receiving Bavituximab Plus Docetaxel Versus Docetaxel Alone
•Clinical Data Strongly Support Advancing Program into Phase III Clinical Development
•Company to Host Conference Call on Monday, September 10, at 11:00 AM EDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced that interim results were presented from its 121 patient randomized, double-blind, placebo-controlled Phase IIb trial in patients with refractory non-small cell lung cancer (NSCLC). The blinded study evaluated two dose levels of bavituximab (bavituximab-containing arms) given with docetaxel versus docetaxel plus placebo (control arm). The interim data showed a statistically significant improvement in overall survival (Hazard Ratio 0.524, p-value .0154) and a doubling of median overall survival (OS) in the bavituximab-containing arms compared to the control arm. The following interim data was presented as part of a late-breaking plenary presentation at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology by David Gerber, M.D., Associate Professor of Internal Medicine at the University of Texas Southwestern Medical Center, a principal investigator in the trial.
----------------------------------------------------------------------------
Treatment Arm
----------------------------------------------------------------------------
Bavituximab Bavituximab Bavituximab
Placebo (1 mg/kg) (3 mg/kg) (Pooled Data)
plus docetaxel plus docetaxel plus docetaxel plus docetaxel
----------------------------------------------------------------------------
Number of
patients (per
protocol 38 40 39 79
population)
----------------------------------------------------------------------------
Median Overall
Surviva lHazard 5.6 months 11.1 months 13.1 months 12.1 months
Ratio (p-value) -- .512 (.0286) .539 (.0714) .524 (.0154)
----------------------------------------------------------------------------
Overall Response 7.9% 15% 17.9% 16.5%
Ratep-value -- .3262 .1895 .2069
----------------------------------------------------------------------------
Progression Free
Survival Hazard 3.0 months 4.2 months 4.5 months 4.2 months
Ratio (p-value) -- .571 (.0794) .65 (.1921) .605 (.067)
----------------------------------------------------------------------------
"This study was a rigorous trial designed to minimize bias and we are encouraged that this trial yielded such positive results in the most important endpoint, overall survival. The positive overall response rates and progression free survival in both bavituximab-containing arms seen earlier in the study has now translated into a statistically significant extension in overall survival for patients, a result rarely achieved in phase II clinical trials." said Joseph Shan, vice president of clinical and regulatory affairs at Peregrine. "The quality of this data gives us a solid foundation for designing a phase III trial with an increased probability of success. We are planning for an end-of-phase II meeting with the FDA as we plan to initiate this trial by mid-2013."
The trial enrolled 121 patients (117 evaluable per the study protocol) with second-line non-squamous NSCLC following one prior chemotherapy regimen at over 40 clinical centers. Patients were equally randomized to 1 of the 3 treatment arms, docetaxel (75mg/m2) plus either placebo, 1 mg/kg bavituximab, or 3 mg/kg bavituximab until disease progression. Approximately 50% of the patients were enrolled in the U.S. and 50% were enrolled internationally with equal distribution between all treatment groups.
"Robust data from this Phase II trial clearly demonstrate a significant benefit in overall survival with a good safety profile in patients receiving bavituximab plus docetaxel compared to those receiving docetaxel plus placebo," said Steven W. King, president and chief executive officer of Peregrine. "We are currently in discussions with several potential pharmaceutical partners who have expressed great interest in our bavituximab oncology program. It is our goal to identify the optimal partner to assist with the design and logistics of a multinational Phase III pivotal trial."
The interim results from the study showed no significant safety differences between the three treatment arms as determined by the trial's independent data monitoring committee. Baseline characteristics were well balanced across all three treatment arms of the study, including performance (ECOG) status, age, gender, and race. Tumor responses were determined in accordance with Response Evaluation Criteria In Solid Tumors (RECIST 1.1) based on blinded central radiology review.
"The median overall survival results from the Proof-of Concept study are truly outstanding and great news for patients. Statistically significant overall survival results at this stage of development are rare and have put us in an excellent position for advancing the program. Our attention is now turned to an end of phase II meeting by year end which will help us define the most efficient path forward to potential regulatory approval," said Robert Garnick, PhD, head of regulatory affairs at Peregrine. "A global Phase III trial designed very similarly to the robust design of this Phase II trial greatly increases bavituximab's likelihood of success."
From Horselover45
Ok One serious note, in none of the articles does it mention what I think is very critical.The fact that MOS hasn't been reached and that figures probably will get better.Have they missed it or refuse to go there??
I miss ole Jazzbeerman...
But he is still 100% on the side of PPHM.
Too bad for his miserable brother! Coulda, shoulda, woulda but now bitter. Still time tho Realist to come to the light, lot more rise to come!
Last 15 minutes... ???
up or down??
3:45 27,100,000 $4.50
Glad I did not sell at $0.47
as my wife asked/demanded me to do 8 weeks ago. Holding since late 2005 & early 2006 and has been a rough ride but this is nice!!!
35,000 shares and holding. Partner coming next, accelerated approval, plus all the other solid cancer tumors Bavi can work against. Liver, prostate, etc etc. and Cotara for GBM.
Hang on boys... STAY GREEDY MY FRIENDS!
where... cannot see on website
JAY CARLSON at PPHM... website info
Hey Jay, website is a little goofed up now. Investor info has scrolled down and now showing below everything else.
May want to fix, lot of people looking I am sure!!!
Good job Jay!!!
20MM shares... 4.17 eom